Personal information

No personal information available

Activities

Employment (4)

University of Minnesota: Minneapolis, US

2023 to present | Graduate Research Assistant (Ingunn Stromnes Lab)
Employment
Source: Self-asserted source
Cara-lin Lonetree

University of Minnesota: Minneapolis, US

2017 to 2020 | Research Technician (Branden Moriarity Lab)
Employment
Source: Self-asserted source
Cara-lin Lonetree

University College London: London, GB

2017 | MSc Research Assistant (Waseem Qasim Lab)
Employment
Source: Self-asserted source
Cara-lin Lonetree

University of Minnesota: Minneapolis, US

2013 to 2016 | Research Technician (Jakub Tolar Lab)
Employment
Source: Self-asserted source
Cara-lin Lonetree

Education and qualifications (2)

University of Minnesota: Minneapolis, US

2022-09 to present | PhD Student (Microbiology, Immunology, & Cancer Biology (MICaB))
Education
Source: Self-asserted source
Cara-lin Lonetree

University College London: London, GB

2016 to 2017 | MSc Cell & Gene Therapy
Education
Source: Self-asserted source
Cara-lin Lonetree

Works (7)

A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes

International Journal of Molecular Sciences
2022-08-28 | Journal article
Contributors: Kanut Laoharawee; Matthew J. Johnson; Walker S. Lahr; Christopher J. Sipe; Evan Kleinboehl; Joseph J. Peterson; Cara-lin Lonetree; Jason B. Bell; Nicholas J. Slipek; Andrew T. Crane et al.
Source: check_circle
Crossref

CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells.

Nature communications
2021-04-23 | Journal article
Contributors: Cara-lin Lonetree
Source: Self-asserted source
Cara-lin Lonetree

Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.

Nature communications
2019-11-19 | Journal article
Contributors: Cara-lin Lonetree
Source: Self-asserted source
Cara-lin Lonetree

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.

Molecular therapy : the journal of the American Society of Gene Therapy
2019-10-15 | Journal article
Contributors: Cara-lin Lonetree
Source: Self-asserted source
Cara-lin Lonetree

CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.

NPJ Regenerative medicine
2016-12-08 | Journal article
Contributors: Cara-lin Lonetree
Source: Self-asserted source
Cara-lin Lonetree

CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia.

Stem cells and development
2016-08-18 | Journal article
Contributors: Cara-lin Lonetree
Source: Self-asserted source
Cara-lin Lonetree

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.

Molecular therapy : the journal of the American Society of Gene Therapy
2015-10-27 | Journal article
Contributors: Cara-lin Lonetree
Source: Self-asserted source
Cara-lin Lonetree